Exelixis (EXEL) valuation
Exelixis P/E ratio history
Exelixis trades at 20.7 times its earnings over the last twelve months and 16.8 times the earnings analysts expect over the next twelve. At its last 8 fiscal year ends its P/E ranged from 8.8 (year to Dec 2018) to 57.3 (year to Jan 2021), with a median of 22.3.
| Fiscal year ended | Price | EPS | P/E | Forward P/E |
|---|---|---|---|---|
| Jan 2, 2026 | $43.58 | $2.78 | 15.7 | 13.9 |
| Jan 3, 2025 | $33.97 | $1.76 | 19.3 | 20.7 |
| Dec 29, 2023 | $23.99 | $0.65 | 36.9 | 26.5 |
| Dec 30, 2022 | $16.04 | $0.56 | 28.6 | — |
| Dec 31, 2021 | $18.28 | $0.72 | 25.4 | 26.9 |
| Jan 1, 2021 | $20.07 | $0.35 | 57.3 | — |
| Jan 3, 2020 | $17.01 | $1.02 | 16.7 | — |
| Dec 28, 2018 | $19.44 | $2.21 | 8.8 | — |
| Dec 31, 2017 | $30.40 | — | n/m | — |
| Dec 30, 2016 | $14.91 | -$0.28 | n/m | — |
n/m: not meaningful (a loss, or earnings close to zero). The daily P/E line is a chart indicator in the app.
Exelixis valuation against its peers
| Company | Market value | P/E | Forward P/E | Price / sales |
|---|---|---|---|---|
| ExelixisEXEL | $17.2B | 20.7 | 16.8 | 6.9 |
| Alnylam PharmaceuticalsALNY | $22.1B | 41.5 | 14.9 | 4.4 |
| BioNTechBNTX | $22.3B | — | — | 7.2 |
| IncyteINCY | $24.4B | 64.0 | 16.2 | 4.1 |
| InsmedINSM | $24.6B | — | — | 16.2 |
| CibusCBRS | $24.7B | — | — | — |
| BiogenBIIB | $37.5B | 109.3 | 16.6 | 3.6 |
| ModernaMRNA | $88.0B | — | — | 39.5 |
| RegeneronREGN | $97.3B | 23.0 | 17.2 | 6.3 |
| Peer median | 52.8 | 16.4 | 6.3 |
Reading these multiples
The P/E divides the share price by earnings per share over the last twelve months; the forward P/E divides it by the earnings analysts expect over the next twelve. Price to sales compares the company's market value with its revenue over the last twelve months. A multiple reads differently from one industry to the next, so the peer group above is the fairer comparison.
See also: EXEL financials · EXEL returns
No forecast, no recommendation. This page describes Exelixis from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.